Table 3.

Knowledge of the HPV vaccine among college students, 2018 (N = 5307)

		Vaccination Status
Knowledge of the HPV	% (n/N*100%)	Vaccination group (164)	Non-vaccination group −5143	χ2	p	OR
Have you ever been heard of HPV vaccine?
	5307	164	5143
Yes	2740 (51.6)	133 (81.1)	2607 (50.7)	60.1	<.001	1.0
No	1859 (35.0)	18 (11.0)	1841 (35.8)			0.2 (0.1–0.3)
Not sure	708 (13.3)	13 (7.9)	695 (13.5)			0.4 (0.2–0.7)
HPV vaccine can100% protect from getting cervical cancer?
	2740	133	2607	29.9	<.001
Yes	67 (2.5)	10 (7.5)	57 (2.2)			1.0
No	2153 (78.6)	116 (87.2)	2037 (78.2)			0.3 (0.2–0.7)
Not sure	520 (19.0)	7 (5.3)	513 (19.7)			0.1 (0.0–0.2)
How do you think of the adaptive population for HPV vaccine?
	2740	133	2607
Both	1762 (64.3)	112 (84.2)	1650 (63.3)	27.6	<.001	1.0
Only female	973 (35.5)	20 (15.0)	953 (36.6)			0.3 (0.2–0.5)
Only male	5 (0.2)	1 (0.8)	4 (0.2)			3.7 (0.4–33.2)
How do you think of the difference between the bivalent vaccine, tetravalent vaccine and nine valent vaccine? (multiple choice)
	2740	133	2607
Protective effect	1300 (47.5)	70 (52.6)	1230 (47.2)	-	-	-
Protected pathogens	1288 (47.0)	91 (68.4)	1197 (45.9)
Price	1051 (38.4)	53 (39.8)	998 (383)
Adaptive population	679 (24.8)	30 (22.6)	649 (24.9)
Adaptive age	673 (24.6)	26 (19.6)	647 (24.8)
Inoculation process	367 (13.4)	18 (13.5)	349 (13.4)
Duration of protection	341 (12.5)	11 (8.3)	330 (12.7)
Side effect	326 (11.9)	11 (8.3)	315 (12.1)
Manufacturer	140 (5.1)	11 (8.3)	129 (5.0)

“How do you think of the difference between the bivalent vaccine, tetravalent vaccine and nine valent vaccine?” is a multiple choice question, was not included in univariable logistic regression.